Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Pediatr Dermatol ; 37(1): 222-223, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31626359

ABSTRACT

Staphylococcal scalded skin syndrome causes widespread skin denudation primarily in infants < 1 year old. Selection of empiric therapy is complicated by rising rates of antibiotic resistance in community-acquired staphylococcal infections. Consistent with a previous study, this retrospective review found that SSSS-associated isolates were more likely to be clindamycin-resistant and less likely to be methicillin-resistant compared to overall staphylococcal infections. We favor cephalosporins and penicillinase-resistant penicillins (eg, oxacillin) for empiric management of SSSS, with consideration of adding MRSA coverage in communities with high MRSA prevalence or failure to improve following several days of treatment.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clindamycin/therapeutic use , Staphylococcal Scalded Skin Syndrome/drug therapy , Staphylococcus aureus/drug effects , Anti-Bacterial Agents/pharmacology , Clindamycin/pharmacology , Drug Resistance, Bacterial , Female , Humans , Infant , Infant, Newborn , Male , Methicillin Resistance , Microbial Sensitivity Tests , Penicillin Resistance , Retrospective Studies , Sensitivity and Specificity , Staphylococcal Scalded Skin Syndrome/microbiology , Staphylococcus aureus/isolation & purification
2.
J Invest Dermatol ; 140(1): 3-12.e1, 2020 01.
Article in English | MEDLINE | ID: mdl-31864431

ABSTRACT

Skin color evaluation contributes to assessment of an individual's cutaneous phenotype. Skin color changes provide important clues to disease progression or treatment response. Skin color is also a predictor of skin cancer risk. Melanin pigment, blood flow, skin thickness, and photoaging contribute to skin color. Melanin, hemoglobin, bilirubin, and carotene are the primary chromophores of skin color. Their concentrations vary depending on the individual's phenotype, anatomic location, external insults of chemical irritants and UVR, and physiological changes. The evaluation and perception of skin color are often subjective. Objective quantification of skin color can be achieved with colorimetric devices such as tristimulus colorimeters. These devices compute the intensity of light reflected from skin and correlate with pigmentation and erythema. Cutaneous color and color changes can be quantified under color organization systems, such as the CIELAB color space, which is standardized by the Commission Internationale de l'Eclairage (CIE). The CIELAB expresses color's lightness, red/green intensity, and yellow/blue intensity, as L*, a*, and b* values, respectively. Additionally, skin color's full spectral characteristics and cutaneous physiology can be measured with spectrophotometers. This article outlines basic principles of the CIELAB color system and how to optimally use colorimetric devices as a skin research tool.


Subject(s)
Erythema/metabolism , Melanins/metabolism , Skin Neoplasms/metabolism , Skin/metabolism , Colorimetry/instrumentation , Colorimetry/methods , Erythema/pathology , Humans , Skin/cytology , Skin Neoplasms/pathology , Skin Physiological Phenomena , Skin Pigmentation , Spectrophotometry , Ultraviolet Rays
3.
PLoS One ; 12(11): e0188135, 2017.
Article in English | MEDLINE | ID: mdl-29145453

ABSTRACT

BACKGROUND: Fibrosing diseases are a leading cause of morbidity and mortality worldwide and, therefore, there is a need for safe and effective antifibrotic therapies. Adenosine, generated extracellularly by the dephosphorylation of adenine nucleotides, ligates specific receptors which play a critical role in development of hepatic and dermal fibrosis. Results of recent clinical trials indicate that tenofovir, a widely used antiviral agent, reverses hepatic fibrosis/cirrhosis in patients with chronic hepatitis B infection. Belonging to the class of acyclic nucleoside phosphonates, tenofovir is an analogue of AMP. We tested the hypothesis that tenofovir has direct antifibrotic effects in vivo by interfering with adenosine pathways of fibrosis using two distinct models of adenosine and A2AR-mediated fibrosis. METHODS: Thioacetamide (100mg/kg IP)-treated mice were treated with vehicle, or tenofovir (75mg/kg, SubQ) (n = 5-10). Bleomycin (0.25U, SubQ)-treated mice were treated with vehicle or tenofovir (75mg/kg, IP) (n = 5-10). Adenosine levels were determined by HPLC, and ATP release was quantitated as luciferase-dependent bioluminescence. Skin breaking strength was analysed and H&E and picrosirus red-stained slides were imaged. Pannexin-1expression was knocked down following retroviral-mediated expression of of Pannexin-1-specific or scrambled siRNA. RESULTS: Treatment of mice with tenofovir diminished adenosine release from the skin of bleomycin-treated mice and the liver of thioacetamide-treated mice, models of diffuse skin fibrosis and hepatic cirrhosis, respectively. More importantly, tenofovir treatment diminished skin and liver fibrosis in these models. Tenofovir diminished extracellular adenosine concentrations by inhibiting, in a dose-dependent fashion, cellular ATP release but not in cells lacking Pannexin-1. CONCLUSIONS: These studies suggest that tenofovir, a widely used antiviral agent, could be useful in the treatment of fibrosing diseases.


Subject(s)
Adenosine Triphosphate/metabolism , Adenosine/metabolism , Antiviral Agents/pharmacology , Connexins/antagonists & inhibitors , Disease Models, Animal , Liver Cirrhosis/prevention & control , Liver/drug effects , Nerve Tissue Proteins/antagonists & inhibitors , Skin Diseases/prevention & control , Skin/drug effects , Tenofovir/pharmacology , Animals , Connexins/physiology , Dose-Response Relationship, Drug , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Nerve Tissue Proteins/physiology , Skin/metabolism
4.
Coron Artery Dis ; 27(7): 592-603, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27414247

ABSTRACT

On the basis of studies that extend back to the early 1900s, regression and stabilization of atherosclerosis in humans has progressed from being a concept to one that is achievable. Successful attempts at regression generally applied robust measures to improve plasma lipoprotein profiles. Possible mechanisms responsible for lesion shrinkage include decreased retention of atherogenic apolipoprotein B within the arterial wall, efflux of cholesterol and other toxic lipids from plaques, emigration of lesional foam cells out of the arterial wall, and influx of healthy phagocytes that remove necrotic debris as well as other components of the plaque. Currently available clinical agents, however, still fail to stop most cardiovascular events. For years, HDL has been considered the 'good cholesterol.' Clinical intervention studies to causally link plasma HDL-C levels to decreased progression or to the regression of atherosclerotic plaques are relatively few because of the lack of therapeutic agents that can selectively and potently increase HDL-C. The negative results of studies that were carried out have led to uncertainty as to the role that HDL plays in atherosclerosis. It is becoming clearer, however, that HDL function rather than quantity is most crucial and, therefore, discovery of agents that enhance the quality of HDL should be the goal.


Subject(s)
Arteries/metabolism , Atherosclerosis/metabolism , Cholesterol, HDL/metabolism , Plaque, Atherosclerotic , Animals , Arteries/drug effects , Arteries/pathology , Atherosclerosis/blood , Atherosclerosis/drug therapy , Atherosclerosis/pathology , Cholesterol, HDL/blood , Disease Models, Animal , Humans , Hypolipidemic Agents/therapeutic use , Remission Induction , Rupture, Spontaneous , Treatment Outcome
5.
Int J Cardiol ; 189: 168-71, 2015 Jun 15.
Article in English | MEDLINE | ID: mdl-25897898

ABSTRACT

The idea that atheroma can regress is no longer a dream. We and others have discovered that decreasing the lipid content can directly lead to macrophage egress and plaque healing. The question, however, has remained as to how to translate these findings to the bedside. Taking advantage of imaging modalities such as intravascular ultrasound (IVUS) and near infrared spectroscopy (NIRS), we demonstrated in the YELLOW (Reduction in Yellow Plaque by Intensive Lipid Lowering Therapy) trial that short term treatment of high dose rosuvastatin treatment can lead to a decrease in lipid content in plaques. It is important to note that optical coherence tomography (OCT), a high resolution imaging modality, was not performed during the first study and therefore, only a very limited assessment of the effect of statin therapy on measures of plaque stabilization could be made. The YELLOW II trial is the first to our knowledge to determine whether these data can be extrapolated and how it relates to HDL function, alterations in macrophage gene expression, and plaque morphology. While tremendous progress has been made, our research serves as a reminder that angiography is simply luminography and it is features such as thin cap fibroatheroma and lipid burden, for example, that likely modulate the syndromes seen in clinical practice. Ongoing studies such as ours may provide novel pathways for diagnosis and therapy, with the ultimate goal of reducing the burden of cardiovascular disease.


Subject(s)
Atherosclerosis/drug therapy , Atherosclerosis/metabolism , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Lipoproteins, HDL/metabolism , Atherosclerosis/pathology , Humans , Rosuvastatin Calcium/therapeutic use , Spectroscopy, Near-Infrared/methods , Tomography, Optical Coherence/methods
7.
Arterioscler Thromb Vasc Biol ; 33(6): 1180-8, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23599441

ABSTRACT

OBJECTIVE: Hypoxia is intimately linked to atherosclerosis and has become recognized as a primary impetus of inflammation. We recently demonstrated that the neuroimmune guidance cue netrin-1 (Ntn1) inhibits macrophage emigration from atherosclerotic plaques, thereby fostering chronic inflammation. However, the mechanisms governing netrin-1 expression in atherosclerosis are not well understood. In this study, we investigate the role of hypoxia in regulating expression of netrin-1 and its receptor uncoordinated-5-B receptor (Unc5b) in plaque macrophages and its functional consequences on these immune cells. APPROACH AND RESULTS: We show by immunostaining that netrin-1 and Unc5b are expressed in macrophages in hypoxia-rich regions of human and mouse plaques. In vitro, Ntn1 and Unc5b mRNA are upregulated in macrophages treated with oxidized low-density lipoprotein or inducers of oxidative stress (CoCl2, dimethyloxalylglycine, 1% O2). These responses are abrogated by inhibiting hypoxia-inducible transcription factor (HIF)-1α, indicating a causal role for this transcription factor in regulating Ntn1 and Unc5b expression in macrophages. Indeed, using promoter-luciferase reporter genes, we show that Ntn1- and Unc5b-promoter activities are induced by oxidized low-density lipoprotein and require HIF-1α. Correspondingly, J774 macrophages overexpressing active HIF-1α show increased netrin-1 and Unc5b expression and reduced migratory capacity compared with control cells, which was restored by blocking the effects of netrin-1. Finally, we show that netrin-1 protects macrophages from apoptosis under hypoxic conditions in a HIF-1α-dependent manner. CONCLUSIONS: These findings provide a molecular mechanism by which netrin-1 and its receptor Unc5b are expressed in atherosclerotic plaques and implicate hypoxia and HIF-1α-induced netrin-1/Unc5b in sustaining inflammation by inhibiting the emigration and promoting the survival of lesional macrophages.


Subject(s)
Atherosclerosis/metabolism , Hypoxia/genetics , Macrophages/cytology , Receptors, Cell Surface/genetics , Animals , Atherosclerosis/physiopathology , Cell Hypoxia/genetics , Cell Hypoxia/physiology , Cell Movement/genetics , Cell Movement/physiology , Cell Survival/genetics , Cell Survival/physiology , Cells, Cultured , Humans , Hypoxia/metabolism , Inflammation/metabolism , Inflammation/physiopathology , Macrophages/metabolism , Mice , Netrin Receptors , RNA, Messenger/metabolism , Receptors, Cell Surface/metabolism
8.
Inflammation ; 36(1): 152-62, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22923002

ABSTRACT

Morning stiffness and increased symptoms of inflammatory arthritis are among the most common manifestations of rheumatoid arthritis (RA). Tumor necrosis alpha (TNF-α), an important mediator of inflammation in RA, regulates the circadian expression of clock proteins, and adenosine A(2A) receptors (A(2A)R) mediate many of the anti-inflammatory and antirheumatic actions of methotrexate, the cornerstone drug in the treatment of RA. We found that A(2A)R activation and TNF-α activated the clock core loop of the human monocytic THP-1 cell line. We further observed that interleukin (IL)-10, but not IL-12, mRNA expression fluctuates in a circadian fashion and that TNF-α and A(2A)R stimulation combined increased IL-10 expression. Interestingly, TNF-α, but not CGS21680, dramatically inhibited IL-12 mRNA expression. The demonstration that A(2A)R and TNF-α regulate the intrinsic circadian clock in immune cells provides an explanation for both the pathologic changes in circadian rhythms in RA and for the adverse circadian effects of methotrexate, such as fatigue.


Subject(s)
ARNTL Transcription Factors/metabolism , CLOCK Proteins/metabolism , Circadian Clocks , Methotrexate/pharmacology , Monocytes/physiology , Receptor, Adenosine A2A/metabolism , Tumor Necrosis Factor-alpha/metabolism , Adenosine/analogs & derivatives , Adenosine/pharmacology , Arthritis, Rheumatoid/metabolism , Cell Line , Circadian Rhythm , Cryptochromes/biosynthesis , Fatigue , Humans , Inflammation , Interleukin-1/genetics , Interleukin-10/genetics , Methotrexate/therapeutic use , Monocytes/metabolism , Period Circadian Proteins/biosynthesis , Phenethylamines/pharmacology , RNA, Messenger/biosynthesis , Tumor Necrosis Factor-alpha/pharmacology
9.
Front Physiol ; 3: 286, 2012.
Article in English | MEDLINE | ID: mdl-22934038

ABSTRACT

Atherosclerosis is the number one cause of death in the Western world. It results from the interaction between modified lipoproteins and cells such as macrophages, dendritic cells (DCs), T cells, and other cellular elements present in the arterial wall. This inflammatory process can ultimately lead to the development of complex lesions, or plaques, that protrude into the arterial lumen. Ultimately, plaque rupture and thrombosis can occur leading to the clinical complications of myocardial infarction or stroke. Although each of the cell types plays roles in the pathogenesis of atherosclerosis, the focus of this review will be primarily on the macrophages and DCs. The role of these two cell types in atherosclerosis is discussed, with a particular emphasis on their involvement in atherosclerosis regression.

10.
Nat Immunol ; 13(2): 136-43, 2012 Jan 08.
Article in English | MEDLINE | ID: mdl-22231519

ABSTRACT

Atherosclerotic plaque formation is fueled by the persistence of lipid-laden macrophages in the artery wall. The mechanisms by which these cells become trapped, thereby establishing chronic inflammation, remain unknown. Here we found that netrin-1, a neuroimmune guidance cue, was secreted by macrophages in human and mouse atheroma, where it inactivated the migration of macrophages toward chemokines linked to their egress from plaques. Acting via its receptor, UNC5b, netrin-1 inhibited the migration of macrophages directed by the chemokines CCL2 and CCL19, activation of the actin-remodeling GTPase Rac1 and actin polymerization. Targeted deletion of netrin-1 in macrophages resulted in much less atherosclerosis in mice deficient in the receptor for low-density lipoprotein and promoted the emigration of macrophages from plaques. Thus, netrin-1 promoted atherosclerosis by retaining macrophages in the artery wall. Our results establish a causative role for negative regulators of leukocyte migration in chronic inflammation.


Subject(s)
Atherosclerosis/immunology , Cell Movement/immunology , Macrophages/immunology , Nerve Growth Factors/metabolism , Plaque, Atherosclerotic/immunology , Tumor Suppressor Proteins/metabolism , Actins/metabolism , Animals , Cells, Cultured , Chemokine CCL19/metabolism , Chemokine CCL2/metabolism , Chimera/metabolism , Gene Deletion , Humans , Mice , Nerve Growth Factors/genetics , Netrin Receptors , Netrin-1 , Neuropeptides/metabolism , Polymerization , Receptors, Cell Surface/metabolism , Tumor Suppressor Proteins/genetics , rac GTP-Binding Proteins/metabolism , rac1 GTP-Binding Protein/metabolism
11.
Proc Natl Acad Sci U S A ; 106(51): 21900-5, 2009 Dec 22.
Article in English | MEDLINE | ID: mdl-19955426

ABSTRACT

The pathogenesis of Huntington's disease (HD) remains elusive. The identification of increasingly early pathophysiological abnormalities in HD suggests the possibility that impairments of striatal medium spiny neuron (MSN) specification and maturation may underlie the etiology of HD. In fact, we demonstrate that HD knock-in (Hdh-Q111) mice exhibited delayed acquisition of early striatal cytoarchitecture with aberrant expression of progressive markers of MSN neurogenesis (Islet1, DARPP-32, mGluR1, and NeuN). Hdh-Q111 striatal progenitors also displayed delayed cell cycle exit between E13.5-15.5 (BrdU birth-dating) and an enhanced fraction of abnormal cycling cells in association with expansion of the pool of intermediate progenitors and over expression of the core pluripotency (PP) factor, Sox2. Clonal analysis further revealed that Hdh-Q111 neural stem cells (NSCs) displayed: impaired lineage restriction, reduced proliferative potential, enhanced late-stage self-renewal, and deregulated MSN subtype specification. Further, our analysis revealed that in addition to Sox2, the core PP factor, Nanog is expressed within the striatal generative and mantle regions, and in Hdh-Q111 embryos the fraction of Nanog-expressing MSN precursors was substantially increased. Moreover, compared to Hdh-Q18 embryos, the Hdh-Q111 striatal anlagen exhibited significantly higher levels of the essential PP cofactor, Stat3. These findings suggest that Sox2 and Nanog may play roles during a selective window of embryonic brain maturation, and alterations of these factors may, in part, be responsible for mediating the aberrant program of Hdh-Q111 striatal MSN specification and maturation. We propose that these HD-associated developmental abnormalities might compromise neuronal homeostasis and subsequently render MSNs more vulnerable to late life stressors.


Subject(s)
Corpus Striatum/pathology , Disease Models, Animal , Huntington Disease/pathology , Stem Cells/cytology , Animals , Mice , Mice, Transgenic , Microscopy, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL
...